The restatement and material weakness signal deep accounting and control failures, likely triggering securities litigation and regulatory scrutiny. The $38.4M asset resolution plan and dilutive rights offering at $3.50/share (vs. recent trading levels) suggest severe capital strain. Monitor for SEC enforcement, shareholder lawsuits, and potential FDIC/OCC actions. The stock faces significant downside risk from dilution and loss of investor confidence.
Price Chart
Executive Summary
BayFirst Financial Corp. filed an amended 10-K (10-K/A) restating its financial statements for fiscal years 2024 and 2025, correcting a cumulative $4.9 million pretax error in deferred origination costs and accrued interest on SBA 7(a) loans, plus a $3.4 million pretax error in gain on sale accounting. The restatement reduces previously reported net income across all affected periods, and management disclosed a material weakness in internal controls over financial reporting related to nonaccrual and charge-off processes. The company also reported a net loss of $24.6 million for FY2025, a sharp reversal from $10.2 million net income in FY2024, driven by a $25.6 million provision for credit losses and $7.3 million in restructuring charges from exiting the SBA 7(a) lending business.
Key Facts
- Restatement corrects $2.8M pretax deferred origination costs and $2.1M pretax accrued interest errors on SBA 7(a) nonaccrual loans, plus $3.4M pretax error in gain on sale accounting.
- Net loss of $24.6 million for FY2025 vs. net income of $10.2 million in FY2024 (as restated).
- Provision for credit losses surged to $25.6 million in FY2025 from $15.4 million in FY2024.
- Noninterest income collapsed to $17.8 million from $58.9 million, driven by a $15.5M drop in gain on sale of government guaranteed loans and $10.9M decline in fair value gains.
- Noninterest expense rose to $70.4 million from $66.8 million, including $7.3 million in restructuring charges from exiting SBA 7(a) lending.
- Total shareholders' equity fell to $81.6 million from $106.6 million at year-end 2024.
- Allowance for credit losses increased to $22.0 million (2.43% of loans at amortized cost) from $15.5 million (1.55%).
- Nonperforming loans (excluding government guaranteed) rose to $16.3 million from $13.6 million.
- Material weakness in internal control over financial reporting identified related to nonaccrual/charge-off processes and gain on sale calculations.
- Dividends suspended since July 2025; $316,946 in erroneously awarded incentive compensation to be clawed back from executives.
- Subsequent events: $38.4M asset resolution plan adjustments, $1.5M impairment on non-marketable equity investment, $1.6M write-down of unamortized premiums, and a rights offering at $3.50/share.
Financial Impact
Restatement reduced retained earnings by $5.99 million as of Dec 31, 2025; FY2025 net loss of $24.6 million vs. prior net income of $10.2 million; provision for credit losses increased by $10.2 million year-over-year.
Risk Factors
- Securities fraud class actions likely following restatement and material weakness disclosure.
- Regulatory enforcement actions from OCC/FDIC/Federal Reserve over internal control failures and capital adequacy.
- Dilution from rights offering at $3.50/share and conversion of preferred shares into 22.9M common shares.
- Further credit losses from the $38.4M asset resolution plan and $1.6M USDA loan premium write-down.
- Potential loss of the Bank if the $1.6M term note secured by 100% of Bank stock cannot be repaid.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001649739-26-000049 |
| Exhibit: ex311-principalexecutiveof.htm | 0001649739-26-000049 |
| Exhibit: ex312-principalfinancialof.htm | 0001649739-26-000049 |
| Exhibit: ex321-principalexecutiveof.htm | 0001649739-26-000049 |
| Exhibit: ex322-principalfinancialof.htm | 0001649739-26-000049 |
| Exhibit: ex231forvisconsent2025rest.htm | 0001649739-26-000049 |
| Document: 0001649739-26-000049-index-headers.html | 0001649739-26-000049 |
| Document: 0001649739-26-000049-index.html | 0001649739-26-000049 |
| Document: 0001649739-26-000049.txt | 0001649739-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13D/A | $6.44 | awaiting T+60 | — | $6.57 (+2.02%) |
Oct 13, 2026 13d ago | SC 13D/A | $5.25 | awaiting T+60 | — | $6.57 (+25.14%) |
Sep 30, 2026 26d ago | 8-K | $6.81 | awaiting T+60 | — | $6.57 (−3.52%) |
Sep 29, 2026 27d ago | 8-K | $7.21 | awaiting T+60 | — | $6.57 (−8.88%) |
Sep 24, 2026 4w ago | 3 | $7.12 | awaiting T+60 | — | $6.57 (−7.72%) |
Sep 24, 2026 4w ago | Press Release | $7.12 | awaiting T+60 | — | $6.57 (−7.72%) |
Sep 1, 2026 7w ago | 8-K | $7.15 | awaiting T+60 | — | $6.57 (+8.11%) |
Aug 27, 2026 8w ago | 8-K | $6.61 | awaiting T+60 | — | $6.57 (−0.61%) |
Aug 25, 2026 8w ago | EFFECT | $7.37 | awaiting T+60 | — | $6.57 (+10.85%) |
Aug 21, 2026 9w ago | S-1/A | $7.31 | awaiting T+60 | — | $6.57 (+10.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers